IPN Ipsen SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 22 - 2023

IPSEN - Buy-back programme - Art 5 of MAR - Week 22 - 2023

Aggregated presentation by day and by market

 



Name of issuer		Identification code of issuer (Legal Entity Identifier) 



Day of transaction		 



Identification code of financial instrument		Aggregated daily volume (in number of shares) 



Daily weighted average price of the purchased shares *		 



Market (MIC Code)
IPSEN549300M6SGDPB4Z94P1101/06/2023FR0010259150284111,21AQEU
IPSEN549300M6SGDPB4Z94P1101/06/2023FR0010259150690111,19CEUX
IPSEN549300M6SGDPB4Z94P1101/06/2023FR001025915024111,26TQEX
IPSEN549300M6SGDPB4Z94P1101/06/2023FR00102591502 979110,74XPAR
IPSEN549300M6SGDPB4Z94P1102/06/2023FR0010259150712110,99AQEU
IPSEN549300M6SGDPB4Z94P1102/06/2023FR0010259150549110,94CEUX
IPSEN549300M6SGDPB4Z94P1102/06/2023FR0010259150458111,01TQEX
IPSEN549300M6SGDPB4Z94P1102/06/2023FR00102591503 681110,81XPAR
* Two-digit rounding after the decimal TOTAL9 377110,86 

Attachment



EN
06/06/2023

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen - April 2025 - Monthly information relative to the total number ...

Ipsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 30 April 2025 83,814,526 Gross total* ...

May 12, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen - Avril 2025 - Information mensuelle relative au nombre total de...

Ipsen - Avril 2025 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social    Information mensuelle relative au nombre total des droits de voteet d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerceet à l’article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : Euronext Paris Code ISIN : FR 0010259150LEI : 549300M6SGDPB4Z94P11 Date Nombre total d’actions composant le capital socialNombre total de droits de vote (1)30 avril 202583 814 526Total brut* des droit...

May 12, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Late-breaking exploratory data highlights the impact of IQIRVO® (elafi...

Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis Additional late-breaking data suggests up to twice as many patients treated with IQIRVO® achieved a clinically meaningful improvement in fatigue compared to placebo after 52 weeks of treatmentIQIRVO dual PPARα/δ activation impacts inflammation and fibrosisPPARα activation linked to fatigue improvement in primary biliary cholangitis PARIS, FRANCE, 7 May 2025 Today, Ipsen (Eur...

May 7, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

De nouvelles données issues d’analyses exploratoires soulignent l’impa...

De nouvelles données issues d’analyses exploratoires soulignent l’impact d’IQIRVO® (élafibranor) sur la fatigue et mettent en lumière son mécanisme d’action sur l’inflammation et les symptômes associés à la cholangite biliaire primitive D’autres données nouvelles suggèrent que jusqu’à deux fois plus de patients traités avec IQIRVO® ont constaté une amélioration cliniquement significative de la fatigue par rapport au placebo après 52 semaines de traitement.La double activation PPARα/δ produit un effet sur l’inflammation et la fibrose.L’activation de PPARα a été associée à une amélioration de...

May 7, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation

Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation PARIS, FRANCE, 06 May 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy & Transformation, effective May 14, 2025. She will serve on the Executive Leadership Team and report directly to Ipsen’s Chief Executive Officer (CEO), David Loew. “We are very pleased to welcome Laura to Ipsen as our EVP for Strategy & Transformation. I have observed Laura’s involvement in major transformation projects across leadin...

May 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch